Hologic, Inc. (NASDAQ:HOLX) Director Sally Crawford sold 12,306 shares of the firm’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $47.61, for a total value of $585,888.66. Following the completion of the sale, the director now directly owns 168,886 shares in the company, valued at $8,040,662.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
HOLX stock opened at $47.72 on Friday. Hologic, Inc. has a 52-week low of $35.10 and a 52-week high of $48.11. The company has a market cap of $13.78 billion, a PE ratio of 21.40, a price-to-earnings-growth ratio of 2.22 and a beta of 0.75. The company has a quick ratio of 0.91, a current ratio of 1.30 and a debt-to-equity ratio of 1.18.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.01. Hologic had a negative net margin of 12.88% and a positive return on equity of 25.59%. The firm had revenue of $830.70 million during the quarter, compared to analyst estimates of $823.22 million. During the same period last year, the business earned $0.55 earnings per share. The business’s revenue was up 5.0% on a year-over-year basis. Sell-side analysts predict that Hologic, Inc. will post 2.41 EPS for the current year.
HOLX has been the topic of several recent analyst reports. Canaccord Genuity reissued a “hold” rating and issued a $41.00 target price on shares of Hologic in a research note on Monday, January 7th. Zacks Investment Research upgraded shares of Hologic from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a report on Monday, February 4th. Piper Jaffray Companies raised their price objective on shares of Hologic to $49.00 and gave the stock an “overweight” rating in a report on Thursday, January 31st. Morgan Stanley lowered shares of Hologic from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $44.00 to $39.00 in a report on Wednesday, January 2nd. Finally, Royal Bank of Canada raised their price objective on shares of Hologic from $40.00 to $46.00 and gave the stock a “sector perform” rating in a report on Friday, November 30th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, nine have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $44.52.
TRADEMARK VIOLATION WARNING: “Sally Crawford Sells 12,306 Shares of Hologic, Inc. (HOLX) Stock” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4239944/sally-crawford-sells-12306-shares-of-hologic-inc-holx-stock.html.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.